STAT+: Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19
After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors…
Category: Pharma
STAT+: Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits
Good morning, everyone, and welcome to another working week, albeit an abbreviated one on this…
STAT+: Regulators in many European countries fail to ensure clinical trial data are available
Amid ongoing concerns over clinical trial transparency, a new report finds “notable gaps” in the…
STAT+: Purdue wants to shower employees with nearly $35 million in different kinds of bonuses
As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug…
STAT+: Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders
And so, another working week will soon draw to a close. Not a moment too…
STAT+: U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing
In the latest bid to compare drug costs, a new study finds that prices for…
STAT+: Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: Mallinckrodt cleared to sell a rare disease drug to a startup, but parents worried over ongoing access
A federal bankruptcy court judge has approved the sale of a rare disease drug to…
STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year
The controversial new Alzheimer’s drug from Biogen (BIIB) would be cost-effective only if priced between…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
.jpg)
STAT+: Pharmalittle: How Biogen and FDA formed a back channel to push an Alzheimer’s drug; Sanofi to dive into mRNA vaccine development
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a…
STAT+: Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug
It was perhaps the most contentious drug approval in decades, shocking drug company executives, insurance…
STAT+: Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?
Gilead Sciences (GILD) released top-line trial data for its Yescarta treatment that may allow the…
STAT+: Pharmalittle: Biogen Alzheimer’s drug will cost Medicare how much? Intellia data suggest a first for genome editing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Johnson & Johnson agrees to pay $230 million to settle opioid case in New York
On the eve of a widely anticipated trial, Johnson & Johnson (JNJ) has agreed to…
STAT+: In an about-face, Health Canada allows a controversial rare disease drug back on the market
In yet another twist in a complicated tale, Health Canada has reinstated approval of a…
STAT+: Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows
The pharmaceutical industry has developed a “hidden web of policy influence” over members of the…
STAT+: As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat rare infection
Over the past few months, thousands of people in India who survived Covid-19 returned to…
STAT+: Pharmalittle: Sanofi dengue vax endorsed by expert CDC panel; Pfizer recalls Chantix as it tests for possible carcinogens
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
STAT+: Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens
After finding potential carcinogens in some lots of Chantix, Pfizer (PFE) late last month halted…
STAT+: Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism
Hello, everyone, and nice to see you again after a day off. We can explain…
STAT+: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug…
STAT+: Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup
Good morning! Elizabeth Cooney here, sitting in for Ed Silverman, who would no doubt be…
STAT+: Teva to pay $925,000 to Mississippi to settle generic price-fixing charges
After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of…
STAT+: Pharmalittle: Biogen isn’t the only company to make big bucks from its Alzheimer’s drug; EU extends Covid-19 vax export block
Hello, everyone, and how are you this morning? Some puffy clouds are hovering over the…
Drug-resistant bacteria pose a growing threat. Can new antibiotics be developed fast enough to combat them?
In 2016, a landmark report was issued on the global problem of antimicrobial resistance. The…
STAT+: Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
As more emphasis is placed on the value of prescription medicines, a new study found…
STAT+: HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies
After a defeat in federal court, the Department of Health and Human Services withdrew an…
STAT+: Pharmalittle: Glaxo CEO under fire ahead of investor meeting; CureVac not giving up on its Covid-19 vaccine
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Medical journal argues a drug maker’s libel suit is really a public relations campaign to chill research
File this under “Not every legal brief is eye-glazing.” Two months ago, Pacira Biosciences (PCRX)…
STAT+: European Union loses bid for faster deliveries of AstraZeneca Covid-19 vaccine
The European Union failed in its attempt to force AstraZeneca (AZN) to speed deliveries of…
STAT+: A California law that bans drug coupons failed to increase generic use
A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater…
STAT+: Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Poll: Many Americans concerned about FDA approval process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment…
STAT+: Billions spent on prescription drug ads may have increased Medicare spending
The large sums of money spent on advertising prescription drugs directly to consumers may have…
STAT+: Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare
Rise and shine, everyone, another busy day is on the way. Even so, there is…
STAT+: Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge
The Open Society Foundations, one of the world’s largest backers of public health initiatives, is…
STAT+: American Medical Association delegates vote to support controversial Covid-19 IP waiver
The American Medical Association delegates voted at their annual meeting to support a controversial proposal…
STAT+: Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics
Good morning, folks. And how are you today? We are in fine spirits, thanks to…
STAT+: Lawmakers revive legislation to accelerate the development of new antibiotics
After months of anticipation, a bipartisan group of U.S. lawmakers is reintroducing bills in the…
STAT+: ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group…
STAT+: Centene to pay $143 million to two states to settle allegations of overcharging Medicaid
Centene (CNC), a major health insurer, agreed to pay a combined $143 million to Ohio…
STAT+: Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT+: Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin
In a first-of-its-kind move, the Mississippi attorney general last week filed a lawsuit accusing several…
STAT+: Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos
Iteos Therapeutics said Monday that it has sold ownership rights to an experimental anti-TIGIT cancer…
STAT+: ‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine
In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag…